February 26, 2026
Three decades ago, in a lab at The Rockefeller University, New York City, Jeffrey Friedman, MD, PhD, observed a paradox that would forever change our understanding […]
February 26, 2026
Accumulating data on the prevention, surveillance, and treatment of chronic hepatitis B (CHB) has resulted in an updated practice guideline, jointly issued by the American Association […]
February 25, 2026
TOPLINE: Patients with higher vs lower polygenic risk scores for susceptibility to inflammatory bowel disease (IBD) experienced more severe disease courses, including higher risks for hospitalizations […]
February 25, 2026
STOCKHOLM — Severe infections requiring hospital treatment were associated with amore than threefold increase in risk for inflammatory bowel disease (IBD) in a prospective cohort study […]
February 25, 2026
TOPLINE: Salcaprozate sodium (SNAC), the absorption enhancer present in oral semaglutide, was associated with reduced abundance of certain fiber-fermenting gut bacteria, lower fecal butyrate levels, elevated […]
February 24, 2026
Feb 24 (Reuters) – Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting […]
February 24, 2026
TOPLINE: Peroral pancreatoscopy-guided electrohydraulic lithotripsy (POPS-EHL) led to complete fragmentation of pancreatic duct stones in most patients with chronic pancreatitis. However, those with stones > 12.8 […]
February 24, 2026
STOCKHOLM — Predictors of primary nonresponse and loss of response to anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease (IBD), including demographic, biochemical, and treatment-related […]
February 23, 2026
Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient […]